Allogene Therapeutics, Inc. Profile Avatar - Palmy Investing

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimer…

Biotechnology
US, South San Francisco [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of ALLO's Analysis
CIK: 1737287 CUSIP: 019770106 ISIN: US0197701065 LEI: - UEI: -
Secondary Listings
ALLO has no secondary listings inside our databases.